Product Description: LKY-047, a Decursin derivative, is a potent and selective reversible competitive cytochrome P45022J2 (CYP2J2) inhibitor with an IC50 of 1.7 μM. LKY-047 is inactive against other human P450s, such as CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A[1].
Applications: Metabolism-sugar/lipid metabolism
Formula: C23H19NO7
References: [1]Nguyen Minh Phuc, et al. LKY-047: First Selective Inhibitor of Cytochrome P450 2J2. Drug Metab Dispos. 2017 Jul;45(7):765-769.
CAS Number: 1954681-29-8
Molecular Weight: 421.40
Compound Purity: 98.85
Research Area: Metabolic Disease; Inflammation/Immunology
Solubility: DMSO : 16.67 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Cytochrome P450